SG11201504704TA - Substituted naphthyridine and quinoline compounds as mao inhibitors - Google Patents

Substituted naphthyridine and quinoline compounds as mao inhibitors

Info

Publication number
SG11201504704TA
SG11201504704TA SG11201504704TA SG11201504704TA SG11201504704TA SG 11201504704T A SG11201504704T A SG 11201504704TA SG 11201504704T A SG11201504704T A SG 11201504704TA SG 11201504704T A SG11201504704T A SG 11201504704TA SG 11201504704T A SG11201504704T A SG 11201504704TA
Authority
SG
Singapore
Prior art keywords
quinoline compounds
mao inhibitors
substituted naphthyridine
naphthyridine
substituted
Prior art date
Application number
SG11201504704TA
Inventor
Jillian Basinger
Graeme Freestone
Varsha Gupta
Alan Kaplan
Chi-Ching Mak
Benjamin Pratt
Vincent Santora
Dipanjan Sengupta
Lino Valdez
Original Assignee
Dart Neuroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Llc filed Critical Dart Neuroscience Llc
Publication of SG11201504704TA publication Critical patent/SG11201504704TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201504704TA 2013-03-14 2014-03-05 Substituted naphthyridine and quinoline compounds as mao inhibitors SG11201504704TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785872P 2013-03-14 2013-03-14
PCT/US2014/020881 WO2014158916A1 (en) 2013-03-14 2014-03-05 Substituted naphthyridine and quinoline compounds as mao inhibitors

Publications (1)

Publication Number Publication Date
SG11201504704TA true SG11201504704TA (en) 2015-07-30

Family

ID=51530146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504704TA SG11201504704TA (en) 2013-03-14 2014-03-05 Substituted naphthyridine and quinoline compounds as mao inhibitors

Country Status (16)

Country Link
US (4) US9150572B2 (en)
EP (1) EP2970125B1 (en)
JP (1) JP6346658B2 (en)
KR (1) KR20150127172A (en)
CN (1) CN105143190B (en)
AU (1) AU2014241759B2 (en)
BR (1) BR112015022202A2 (en)
CA (1) CA2895287A1 (en)
HK (1) HK1220185A1 (en)
IL (1) IL240805B (en)
MX (1) MX2015011144A (en)
NZ (1) NZ711598A (en)
RU (1) RU2661156C2 (en)
SG (1) SG11201504704TA (en)
TW (1) TWI657078B (en)
WO (1) WO2014158916A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346658B2 (en) 2013-03-14 2018-06-20 ダート・ニューロサイエンス・（ケイマン）・リミテッド Substituted naphthyridine and quinoline compounds as MAO inhibitors
SG11201702154WA (en) * 2014-09-17 2017-04-27 Dart Neuroscience Cayman Ltd Mao-b inhibitors and rehabilitation
CN104496998B (en) * 2014-12-15 2017-07-11 陕西嘉禾生物科技股份有限公司 A kind of preparation method of hydrogen spiral shell [1, the 3 dioxolane 2] quinoline of 1 ' benzyl, 2 ' ketone 5 ', 7 ', 8 ' three
WO2016125187A1 (en) 2015-02-03 2016-08-11 Council Of Scientific & Industrial Research Novel quinoline derivatives and preparation thereof
WO2016179428A2 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Cognitive test execution and control
WO2017133752A1 (en) * 2016-02-04 2017-08-10 Merck Patent Gmbh [1,5]naphthyridine compounds and polymers as semiconductors
EP3512840B1 (en) * 2016-09-14 2024-03-06 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
EP3519816A4 (en) * 2016-09-29 2020-05-06 The Regents of the University of California Compounds for increasing neural plasticity
CN107216331B (en) * 2017-07-07 2019-06-18 华南理工大学 A kind of Tetrahydronaphthyridderivates simultaneously tetrahydro quinazoline derivative and its synthetic method and application
KR102005019B1 (en) * 2018-04-04 2019-07-31 한국과학기술연구원 A composition for preventing and treating stroke
CN108658977A (en) * 2018-04-12 2018-10-16 苏州康润医药有限公司 A kind of synthetic method of the bromo- 1,5- naphthyridines -3- formic acid of 7-
BR112021016620A2 (en) 2019-02-27 2021-11-03 Univ California Azepino-Indoles and Other Heterocycles for the Treatment of Brain Disorders
JP2022523774A (en) 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア N-substituted indole and other heterocyclic compounds for the treatment of brain disorders
CN112939952A (en) * 2021-02-02 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 3-hydroxy chalcone derivative and application thereof
CN112898276A (en) * 2021-02-02 2021-06-04 深圳市第二人民医院(深圳市转化医学研究院) Chalcone derivative and application thereof
CN114437068A (en) * 2022-02-21 2022-05-06 深圳市儿童医院 Naphthyridine derivative and application thereof as monoamine oxidase inhibitor

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138540A (en) * 1966-09-19 1969-01-01 Ici Ltd Quinoline derivatives
SU550385A1 (en) * 1975-09-22 1977-03-15 Институт Биологической И Медицинской Химии Амн Ссср 8- (-Methyl-β-propinyl-2) -aminomethylquinoline as an inhibitor of monoamine oxidase and its preparation
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH04295470A (en) 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd 1,2,4-oxadiazole derivative having monoamine oxidase b enzyme inhibiting activity and its production
US5510361A (en) 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
DE69738809D1 (en) 1996-11-08 2008-08-14 Nippon Chemiphar Co MEANS FOR REDUCING OVEN FATS
EP0994095A1 (en) 1996-12-24 2000-04-19 Nippon Chemiphar Co., Ltd. Propionic acid derivatives
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
EP1355669B1 (en) 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
JP2002322163A (en) * 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd Piperazine derivative
FR2834640B1 (en) 2002-01-11 2004-09-24 Lipha PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID AND ITS USE FOR TREATING DIABETES
JP4120586B2 (en) 2002-01-18 2008-07-16 アステラス製薬株式会社 2-acylaminothiazole derivatives or salts thereof
US6761089B2 (en) 2002-07-01 2004-07-13 Proqual, Llc Tool for removing screws with damaged heads
PE20050077A1 (en) 2002-09-20 2005-03-01 Hoffmann La Roche DERIVATIVES OF 4-PYRROLIDINE-PHENYL-BENZYL-ETHER
EP1643352A4 (en) 2003-07-02 2009-03-04 Satoshi Yamatake Database system
EP1680127B1 (en) 2003-10-23 2008-10-15 F. Hoffmann-La Roche Ag Benzazepine derivatives as mao-b inhibitors
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
RU2392276C2 (en) 2005-03-29 2010-06-20 Ньюрон Фармасьютикалс С.П.А. Substituted aminoalkyl- and amidoalkylbenzopyran derivatives
WO2007008963A1 (en) 2005-07-13 2007-01-18 Jenrin Discovery Mao-b inhibitors useful for treating obesity
AU2007221020B9 (en) 2006-02-28 2013-04-04 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
US20090053140A1 (en) 2007-05-15 2009-02-26 Roderick Euan Milne Scott METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
WO2009029632A1 (en) 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
MX2010014394A (en) * 2008-06-20 2011-05-19 Rottapharm Spa 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands.
WO2010051196A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
ES2343347B2 (en) 2009-01-27 2011-12-07 Universidade De Santiago De Compostela USE OF DERIVATIVES OF 3-PHENYLCUMARINES 6-SUBSTITUTES AND PREPARATION OF NEW DERIVATIVES.
KR101220182B1 (en) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 Azole derivatives, composition comprising thereof and method for treating parkinson's disease using the compounmd
JP6346658B2 (en) 2013-03-14 2018-06-20 ダート・ニューロサイエンス・（ケイマン）・リミテッド Substituted naphthyridine and quinoline compounds as MAO inhibitors

Also Published As

Publication number Publication date
US9150572B2 (en) 2015-10-06
HK1220185A1 (en) 2017-04-28
CN105143190A (en) 2015-12-09
IL240805B (en) 2018-07-31
US20160074377A1 (en) 2016-03-17
RU2661156C2 (en) 2018-07-12
AU2014241759B2 (en) 2017-10-19
EP2970125A4 (en) 2016-07-27
US9102674B2 (en) 2015-08-11
US20140315944A1 (en) 2014-10-23
US9675605B2 (en) 2017-06-13
US20170312263A1 (en) 2017-11-02
US9956213B2 (en) 2018-05-01
MX2015011144A (en) 2016-02-09
WO2014158916A1 (en) 2014-10-02
IL240805A0 (en) 2015-10-29
US20140275548A1 (en) 2014-09-18
EP2970125B1 (en) 2018-07-18
TWI657078B (en) 2019-04-21
KR20150127172A (en) 2015-11-16
JP6346658B2 (en) 2018-06-20
CN105143190B (en) 2017-08-18
CA2895287A1 (en) 2014-10-02
BR112015022202A2 (en) 2017-07-18
NZ711598A (en) 2016-09-30
TW201506012A (en) 2015-02-16
AU2014241759A1 (en) 2015-09-17
RU2015137619A (en) 2017-04-20
JP2016512256A (en) 2016-04-25
EP2970125A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
HK1220185A1 (en) Substituted naphthyridine and quinoline compounds as mao inhibitors mao
HK1248138A1 (en) Imidazopyridine compounds and uses thereof
IL279682A (en) Benzoquinolone inhibitors of vmat2
HK1219735A1 (en) Quinoline derivative
HK1218547A1 (en) Novel quinazolinones as bromodomain inhibitors
EP2970340A4 (en) Beta-lactamase inhibitors
EP2943204A4 (en) Beta-lactamase inhibitors
HK1216531A1 (en) Novel inhibitors
EP2915806A4 (en) Novel quinoline compound and use thereof
GB201312318D0 (en) Novel methods and compounds
EP2885291A4 (en) Vegfr3 inhibitors
HK1221645A1 (en) Benzoquinolone inhibitors of vmat2 vmat2
EP2885292A4 (en) Vegfr3 inhibitors
HK1213885A1 (en) Imidazo-triazine derivatives as pde10 inhibitors pde10 -
EP2968324A4 (en) Substituted pyridizinone derivatives as pde10 inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors